| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
9-(β-D-Xylofuranosyl)adenine targets adenosine signaling pathways and nucleotide metabolism. As an adenosine analog, it mimics the structure of adenosine and can interfere with adenosine receptors, adenosine transporters, or adenosine-metabolizing enzymes. The compound's mechanism of action likely involves disruption of purine nucleotide metabolism and interference with DNA/RNA synthesis in cancer cells, leading to inhibition of cancer progression.
|
|---|---|
| ln Vitro |
In vitro, 9-(β-D-Xylofuranosyl)adenine functions as an adenosine analog that can interfere with cellular metabolism. Adenosine analogs are known to act as smooth muscle vasodilators and have been shown to inhibit cancer progression. The compound's activity as a nucleoside analog allows it to be incorporated into nucleic acids or to interfere with nucleotide metabolism, potentially leading to inhibition of cell proliferation in cancer cells.
|
| ln Vivo |
In vivo, 9-(β-D-Xylofuranosyl)adenine has been found to be effective in prolonging the survival time of mice bearing TA3 or Ehrlich ascites tumors. This demonstrates the compound's in vivo antitumor efficacy in animal models of cancer. The prolongation of survival time in tumor-bearing mice indicates that the compound can inhibit tumor progression and extend lifespan in preclinical models.
|
| Enzyme Assay |
For non-cellular in vitro assays, 9-(β-D-Xylofuranosyl)adenine is evaluated for its interactions with adenosine receptors, adenosine transporters, or adenosine-metabolizing enzymes. Binding affinity studies using radioligand binding assays or surface plasmon resonance may be performed to characterize the compound's interactions with its molecular targets. Enzyme inhibition assays may assess the compound's effects on adenosine deaminase or other enzymes involved in purine metabolism.
|
| Cell Assay |
For in vitro cellular assays, 9-(β-D-Xylofuranosyl)adenine is tested in cancer cell lines to assess its antiproliferative effects. Cells are treated with serial dilutions of the compound, and cell viability and proliferation are measured using standard assays. The compound's effects on nucleotide metabolism, DNA synthesis, and cell cycle progression may be assessed using radioisotopic labeling, flow cytometry, or other analytical techniques. Additional assays may evaluate the compound's vasodilatory activity in smooth muscle cell models.
|
| Animal Protocol |
For in vivo animal studies, 9-(β-D-Xylofuranosyl)adenine has been evaluated in mice bearing TA3 or Ehrlich ascites tumors. In these studies, tumor-bearing mice are treated with the compound, and survival time is monitored. The compound's ability to prolong survival time in tumor-bearing mice demonstrates its in vivo antitumor efficacy. Additional studies may assess tumor growth inhibition, body weight changes, and histopathological examination of tumors.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 9-(β-D-Xylofuranosyl)adenine are limited. As a nucleoside analog, it is expected to have moderate oral bioavailability and may be transported into cells via nucleoside transporters. The compound may be metabolized by nucleoside-metabolizing enzymes or incorporated into nucleic acids. Further pharmacokinetic studies would be needed to determine its absorption, distribution, metabolism, and excretion profile. The compound should be stored at room temperature.
|
| Toxicity/Toxicokinetics |
Toxicological data for 9-(β-D-Xylofuranosyl)adenine are limited. As a nucleoside analog, it may have dose-dependent toxicities affecting rapidly dividing cells including bone marrow progenitors and gastrointestinal epithelial cells. Comprehensive toxicology studies would be required for therapeutic development. The compound is for research use only and not for human use.
|
| References | |
| Additional Infomation |
9-β-D-xylose-furanose adenine is a purine nucleoside in which adenine is linked to xylose-furanose via a β-N(9)-glycosidic bond. It is functionally related to adenine.
9-(β-D-Xylofuranosyl)adenine is an adenosine analog that was synthesized long ago and found to be effective in prolonging the survival time of mice bearing TA3 or Ehrlich ascites tumors. Adenosine analogs mostly act as smooth muscle vasodilators and have also been found to suppress cancer progression. The compound consists of an adenine base linked to a xylofuranose sugar via a beta-N(9)-glycosidic bond and has a molecular weight of 267.24. |
| Molecular Formula |
C10H13N5O4
|
|---|---|
| Molecular Weight |
267.24
|
| Exact Mass |
267.097
|
| CAS # |
524-69-6
|
| PubChem CID |
447916
|
| Appearance |
White to off-white solid powder
|
| Density |
2.08g/cm3
|
| Boiling Point |
676.3ºC at 760 mmHg
|
| Melting Point |
257.0-257.5ºC (0.4 H2O)
|
| Flash Point |
362.8ºC
|
| Index of Refraction |
1.907
|
| LogP |
-1.1
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
335
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@H]([C@H](O3)CO)O)O)N
|
| InChi Key |
OIRDTQYFTABQOQ-GAWUUDPSSA-N
|
| InChi Code |
InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6+,7-,10-/m1/s1
|
| Chemical Name |
(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (467.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7420 mL | 18.7098 mL | 37.4195 mL | |
| 5 mM | 0.7484 mL | 3.7420 mL | 7.4839 mL | |
| 10 mM | 0.3742 mL | 1.8710 mL | 3.7420 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
